Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN1033 in Sarcopenia – Randomized Double-Blind Placebo-Controlled Phase 2 Trial
2013-003134-33Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Sarcopenia comparing REGN1033 with Placebo (2 arms). Primary endpoint: Percent change in total lean body mass. Started Nov 2013; status: completed.
02
Drugs
trevogrumab
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on 2013-003134-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003134-33.